

1 **Title:** The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson's Disease: An  
2 Updated Systematic Review

3 **Running Title:** COVID-19 and Parkinson's Disease

4 **Authors:** Vikash Jaiswal<sup>1,2</sup>, Danah Alquraish<sup>1</sup>, Zouina Sarfraz<sup>\*1,3</sup>, Shavy Nagpal<sup>4</sup>, Prakriti Singh  
5 Shrestha<sup>4</sup>, Dattatreya Mukherjee<sup>\*\*5</sup>, Prathima Guntipalli<sup>1</sup>, Azza Sarfraz<sup>1,6</sup>, Diana F Sánchez  
6 Velazco<sup>7</sup>, Arushee Bhatnagar<sup>1</sup>, Saloni Savani<sup>1</sup>, Elmjedina Halilaj<sup>1</sup>, Samir Ruxmohan<sup>8</sup>, Wilson  
7 Cueva<sup>8</sup>

8 **Institutions:**

- 9 1. Larkin Health System, South Miami, FL, USA
- 10 2. AMA School of Medicine, Makati, Philippines
- 11 3. Fatima Jinnah Medical University, Lahore, Pakistan
- 12 4. The Research Institute of St. Joe's Hamilton, ON, Canada
- 13 5. International School, Jinan University, P.R China
- 14 6. Aga Khan University, Karachi, Pakistan
- 15 7. Cayetano Heredia Peruvian University, Lima, Peru
- 16 8. Department of Neurology, Larkin Community Hospital, South Miami, FL, USA

17

18 **\*Corresponding Author:** Zouina Sarfraz MBBS, Division of Research and Academic Affairs,  
19 Larkin Health System, 7031 SW 62nd Avenue South Miami, FL 33143, USA. Email:  
20 [zouinasarfraz@gmail.com](mailto:zouinasarfraz@gmail.com)

21 **\*\*Medrxiv Corresponding:** Dattatreya Mukherjee, MBBS Student, Jinan University, P.R China  
22 [Dattatreyamukherjee4u@outlook.com](mailto:Dattatreyamukherjee4u@outlook.com)

23

24 #All Authors have Contributed Equally and Significantly

25 **Conflicts of interest:** All authors declare no conflict of interest.

26 **Funding:** None obtained.

27 **Acknowledgments:** We would like to acknowledge Samia Jahan, Madiha Zaidi, Wanessa  
28 Matos, Sana Javed, Asma Mohammadi, and Sujun Poudel for their early contributions. All

29 authors are thankful to Jack Michel, and the Larkin Health System for boosting scholarly  
30 research pursuits.

### 31 **Abstract**

32 **Background:** COVID-19 has affected global communities with multiple neurological  
33 complications in addition to other critical medical issues. COVID-19 binds to the host's  
34 angiotensin-converting enzyme2 (ACE2) receptors, which are expressed in the neurons and glial  
35 cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors are  
36 abundantly expressed on dopamine neurons, which may worsen the prognosis of motor  
37 symptoms in Parkinson's disease (PD). SARS-CoV-2 may lead to an indirect response via  
38 immune-mediated cytokine storms and propagate through the CNS leading to damage. PD is also  
39 been associated with certain post-viral infections apart from COVID-19, such as HSV,  
40 Influenzavirus A, Measles virus, Cytomegalovirus, and Mumps.

41  
42 **Objective:** In this systematic review, we aim to provide a thorough analysis of associations  
43 between COVID-19 and neurological outcomes for patients with PD.

44  
45 **Methods:** Using PRISMA statement 2020, a systematic review was conducted to isolate  
46 confirmed COVID-19 patients and analyze the PD-associated neurological outcomes. A  
47 systematic literature search was conducted using the following databases: PubMed, Science  
48 Direct, Google Scholar, and Cochrane databases. The following keywords were used  
49 "COVID19, SARS-CoV-2, Parkinson's disease, Pandemic, Mortality." A modified Delphi  
50 process was employed to include the studies and ensure that the clinical outcome measures were  
51 addressed.

52  
53 **Results:** Of the 355 records located during the initial round of screening, 16 were included in the  
54 final synthesis. Of PD patients who tested positive for SARS-CoV-2, worsening motor  
55 symptoms and other viral-associated symptoms were reported. These symptoms included  
56 bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and  
57 legs. Encephalopathy was presented in two of the included studies. Increased mortality rates  
58 were identified for hospitalized patients due to COVID-19 and PD as compared to other patient  
59 groups, albeit with limited generalizability due to high bias of included studies.

60  
61 **Conclusion:** Patients with PD may experience substantial worsening of motor and non-motor  
62 symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical  
63 studies in the future ought to explore the disease severity and neurological outcomes in COVID-  
64 19 positive patients with PD as compared to non-PD patients, in addition to understanding the  
65 role of ACE2 in increased vulnerability to contracting the infection and as a treatment modality.

66  
67 **Keywords:** COVID-19, Parkinson's disease, SARS-CoV-2, Neurological, ACE2

68

69

70

71

72

73

## 74 **1. Introduction**

75 At the onset of the coronavirus disease (2019) pandemic on 31 December 2019, many  
76 reports found that SARS-CoV-2 primarily caused pneumonia-like symptoms <sup>1</sup>. This virus  
77 emerged as a global threat and a public health emergency of imminent concern across countries  
78 worldwide, with exponential transmission capability. As of May 25, 2021, there have been 167  
79 million confirmed cases of COVID-19, with reported deaths up to 3.47 million globally <sup>2</sup>.  
80 COVID-19 belongs to a novel member of the coronaviridae family named SARS-CoV-2 (Severe  
81 Acute Respiratory Syndrome Coronavirus 2) <sup>3</sup>. Coronaviruses are enveloped positive single-  
82 stranded RNA viruses, and the 3' terminal contains structural proteins. The Spike (S) protein  
83 allows the virus to fuse to host cell membranes in proximity to infected and uninfected cells <sup>4</sup>. A  
84 surge in the levels of cytokines (TNF $\alpha$ , IL $\beta$ 6, IL $\beta$ 8, and IL $\beta$ 10) have been reported, leading  
85 to a suppression of T-cell response <sup>5</sup>. To date, a multitude of studies have assessed the role of  
86 angiotensin-converting enzyme2 (ACE2) receptors in increasing vulnerability of hosts, however,  
87 there is a dearth of analysis on the role of ACE inhibitors in treating Parkinson's disease (PD)  
88 patients. In this systematic review, we aim to provide an updated, thorough analysis of  
89 associations between COVID-19 and neurological outcomes for patients with PD.

90 Coronavirus disease (2019) has prompted many challenges in global healthcare systems  
91 due to its unpredictability and unique manifestations in 1) pulmonary, 2) neurological, 3)  
92 cardiovascular, 4) gastrointestinal, and 5) hematological systems. The scientific literature  
93 confirms the presence of SARS-CoV-2 in CSF, in addition to respiratory, fecal, and blood

94 samples. In about 36.4% of cases, neurological findings have been identified, ranging from  
95 dizziness, headache, hyposmia, hypogeusia, dysphagia, muscle pain, seizures, and loss of  
96 consciousness <sup>6</sup>. COVID-19 also influences socializing factors such as the surge in isolation-  
97 induced neurological effects, limited social activities possibly leading to short or long-term  
98 neuropsychiatric disorders.

99 We hypothesize that COVID-19 induced lockdowns, self-isolation, and the fears  
100 associated with contracting disease accentuate neuro-psychiatric problems such as depression  
101 and cognition. **Figure 1** illustrates motor and non-motor manifestations in addition to autonomic  
102 manifestations that are pertinent in the assessment of the clinical outcomes of confirmed positive  
103 PD patients. Given the dearth of data, we aim to provide a comprehensive and updated  
104 systematic review to guide clinical care and practice in understanding the effects of COVID-19  
105 on Parkinson's disease.

Parkinson's Disease Clinical Manifestations		
<b>Motor manifestations</b> 1. Resting tremors 2. Rigidity 3. Bradykinesia 4. Postural instability	<b>Non-motor manifestations</b> 1. Cognitive adverse effects 2. Neuropsychiatric complications 3. Depression 4. Apathy	<b>Autonomic manifestations</b> 1. Hypotensive episodes 2. Erectile dysfunction 3. Bladder complications

106  
107 **Figure 1.** Clinical manifestations of Parkinson's disease.  
108


109  
110  
111

112  
113  
114  
115  
116  
117  
118  
119

## **2. Methodology**

### **2.1. Search strategy**

121 Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)  
122 2020 statement, a systematic literature search was performed from December 2019 through May  
123 2021 <sup>7</sup>. The following set of keywords were used, employing the Boolean (and/or) logic:  
124 “COVID19”, “SARS-CoV-2”, “Parkinson’s disease,” “Pandemic,” “Mortality.” We searched the  
125 following databases, namely, PubMed, Cochrane, Science Direct, EMBASE, and Google  
126 Scholar. A modified Delphi approach was utilized to include studies and ensure that the clinical  
127 outcome measures are identified in a systematic and unanimous order in the included studies <sup>8</sup>.  
128 The PRISMA flowchart is illustrated in **Figure 2**.



129

130 **Figure 2.** PRISMA Flowchart.

## 131 2.2. Study selection

132 We included studies with confirmed COVID-19 disease who had a history of Parkinson's  
133 disease. Only studies published in English and with open access availability were included. In  
134 total, 355 records were located during the initial round of screening. During this round of  
135 screening, all authors scanned the abstracts and titles independently, which led to the location of

136 155 records. In the second screening round, full-text records were screened, and 125 articles that  
137 met the exclusion criteria were removed. During the third screening round, 84 records were  
138 screened for eligibility. In total, 35 records were excluded as non-PD patient groups were  
139 present, 16 records had incomplete data for sourcing, and 16 of the full-text records present with  
140 post-COVID-19 PD development, which met the exclusion criteria. Finally, 16 articles were  
141 included in the qualitative synthesis.

### 142 **2.3. Eligibility criteria**

143 The inclusion criteria for studies and the target population consisted of 1) COVID-19  
144 patients with Parkinson's disease, 2) patients diagnosed with Parkinson's disease before COVID-  
145 19 infection, 3) age group > 21 years old, 4) male and/or female, and 5) available articles in  
146 English language only. Studies were excluded if they met one or more of the following criteria 1)  
147 -COVID-19 negative PD patients, 2) studies on pregnant women, 3) the pediatric population, 4)  
148 crossover study design, 5) commentaries/perspective pieces.

### 149 **2.4. Data extraction and synthesis**

150 The following data were extracted from eligible studies: serial number, author and year,  
151 study design, sample size, gender, age, comorbidities, disease duration, PD outcomes, COVID-  
152 19 associated symptoms. A shared spreadsheet was used to input data, which was extracted  
153 independently by three authors for analysis and cumulative result interpretation (V.J., D.A.,  
154 S.N.). The fourth reviewer (Z.S.) solved any discrepancies in data extraction and reach a  
155 consensus in case of any disagreements.

156 Quality assessment was conducted by two authors (V.J. and Z.S.), who independently  
157 assessed the (1) criteria of diagnosis of COVID-19 patients, (2) confirmed diagnosis of PD  
158 before the COVID-19 pandemic, (3) PD sequelae in the included studies. A descriptive analysis


159 was conducted and presented for the included studies. Percentages and means were presented.  
160 Frequent outcomes were reported if they have a frequency of at least 5% or more in the included  
161 studies. The term PD complications were based on the motor, non-motor, and autonomic  
162 complications mentioned in **Figure 1**.

### 163 **2.5. Role of Funding**

164 No funding was obtained for this study.

### 165 **3. Results**

166 Of the 355 records identified during the first round of screening, 16 studies comprising, 7  
167 (43.8%) were case reports and case series, 4 (25%) case-control studies, 2 (12.5%) cross-  
168 sectional, 2 (12.5%) cohort and 1 (6.25%) retrospective study were added (**Figure 3**)<sup>910</sup>  
169 <sup>1112131415161718192021222324</sup>. In total, a synthesis of 1290 PD patients with COVID-19 and the  
170 characteristics of all included studies are presented in **Table 1**.



171  
172 **Figure 3.** Types of studies included in the systematic review.

173 Male gender was predominant in 10 studies<sup>9101112131415161718</sup> and female gender was the  
174 predominant one in 6 studies<sup>171920212223</sup>. Of the available patient data, the cumulative mean of  
175 age in years of included patients was 76.9 years. The average disease duration spanned 11 years



176 before the incidence of COVID-19 disease. Majority of the included patients presented with  
177 comorbid conditions, comprising of hypertension<sup>913151620212324</sup>, diabetes<sup>10121618192021</sup>, obesity<sup>9</sup>,  
178 dyslipidemia<sup>21</sup>, cardiovascular disease<sup>910141519202124</sup>, immunocompromised<sup>91524</sup>, COPD<sup>9131418</sup>,  
179 asthma<sup>18</sup>, chronic renal and liver diseases<sup>181924</sup>. Of the PD patients that were tested and positive  
180 infection with SARS-CoV-2, worsening of motor symptoms<sup>9101114151618192123</sup> including  
181 bradykinesia, tremors, gait disturbances, delirium, and dementia<sup>1319</sup> were noted; severe spasms  
182 of the arms and legs<sup>22</sup> were found, with individual study percentages of motor symptoms  
183 ranging from 19% to 100%, along with other COVID-19 symptoms. Encephalopathy was also  
184 one of the major symptoms, which presented in 2 (12.5%) of the 16 studies<sup>in 2023</sup>. Mortality rates  
185 for PD patients with COVID-19 who were hospitalized ranged from 5.7% to 100%  
186<sup>910111213141516181920212224</sup>. The mortality was notably 100% due to the inclusion of case reports.

#### 187 4. Discussion

188 To our best understanding, this is the first systematic review to assess clinical outcomes  
189 of Parkinson's disease (PD) in confirmed COVID-19 patients with a pre-pandemic PD diagnosis.  
190 Wide varieties of neurological consequences have been reported in scientific literature among  
191 COVID-19 positive patients<sup>252627282930313233</sup>. Neurological symptoms comprised of the following  
192 include those associated with core dysfunction (fatigue, headache, confusion, stroke<sup>34</sup>, dizziness,  
193 syncope<sup>35</sup>, seizure, anorexia, and insomnia)<sup>363738</sup>, central-peripheral mixture (Guillain Barre  
194 syndrome)<sup>39</sup>, enteric, or peripheral nervous systems dysfunction (anosmia, ageusia, myoclonus  
195<sup>40</sup>, neuropathic pain, and myalgia)<sup>41</sup>. The increase in hospital admission and mortality rates in  
196 PD and other chronic neurological diseases during the COVID-19 pandemic is of imminent  
197 concern as the long-term sequelae are currently undetermined. Most neurological diseases,  
198 including PD, are dose-dependent on prescribed medications for symptomatic management. With

199 the compounded neuropsychiatric symptoms due to social isolation and outpatient clinics,  
200 temporarily being suspended and irregular visits, these are causative in worsening PD symptoms  
201 among COVID-19 patients <sup>42</sup>.

202 In this systematic review, we included studies with COVID-19 positive patients with a  
203 prior history of Parkinson's disease. The most common manifestations due to COVID-19 in PD  
204 patients were found to be motor dysfunction. The majority of the studies showed a common  
205 motor deficit domain in the range of moderate to severe. Some of the patients presented with  
206 delirium, dementia, and encephalopathy among other COVID-19 complications. We posit that  
207 this may be related to the ACE2 mechanism in the nervous system. It is postulated that SARS-  
208 CoV-2 enters the cell, increases the activity of T cells, causing vasodilation, thrombosis, and  
209 hypoxemia, which may then lead to stroke and seizures. One theory supports the effect of the  
210 virus by stating that SARS-COV-2 attacks ACE 2 receptors in a multi-organ manner, targeting  
211 the brain. A study found that ACE2 receptors act locks on cells and the SARS-CoV-2 spike  
212 proteins act rapidly multiply on entering the cells. These ACE2 receptors control tissues in the  
213 eye, reproductive system, renal-excretory, digestive, and respiratory system, and 21 different  
214 regions of the brain, which require further deliberation in PD patients <sup>43</sup>.

215 We found that the average age of all participants was 76.9 years with a male  
216 predominance, in addition to a prior disease duration of 11 years. The majority of the patients  
217 reported the presence of other comorbidities, of which the following were the most common:  
218 hypertension, diabetes, obesity, dyslipidemia, cardiovascular disease, immunocompromised,  
219 COPD, asthma, chronic renal and chronic liver diseases. Documented COVID-19 neurological  
220 complications include stroke, especially in younger patients, reflecting the hypercoagulable state,  
221 leukoencephalopathy, and hemorrhagic leukoencephalopathy. Although direct encephalitis was

222 documented, it is rare but does occur. Further, cranial neuropathies are also infrequent but  
223 include the loss of sense of smell (cranial nerve 1) and Bell's palsy (cranial nerve 7)<sup>44</sup>. There  
224 have been neurocognitive signs, particularly in older age groups that warrant further associations  
225 to PD symptoms, clinical care, and management in the short and long term.

## 226 **5. Limitations**

227 We had certain limitations. The first included the presence of confounder factors. These  
228 related to the finding that multiple studies of patients with elderly PD patients had other  
229 comorbidities, possibly leading to an overrepresentation of findings. Secondly, the duration of  
230 PD and the severity of the pre-pandemic symptoms possibly influenced the synthesis of clinical  
231 outcomes due to COVID-19 infection. Thirdly, pertinent information, including prior and current  
232 medications and compliance to treatment was lacking, leading to a lack of generalized  
233 recommendations for PD and COVID-19 clinical care. While the inclusion of case reports may  
234 deviate from generalizations in our findings, we believe they are pertinent for long-term PD  
235 patients with acquired COVID-19 infection.

## 236 **6. Conclusion**

237 COVID-19 has a peaked mortality rate in older age groups, compounded with comorbid  
238 conditions. The CNS is increasingly susceptible to SARS-CoV-2, deteriorating neurological  
239 findings, particularly in patients with PD. We find that motor dysfunction, delirium, dementia,  
240 severe spasms of arms and legs, and encephalopathy are pertinent clinical findings in PD patients  
241 and ought to be addressed in current care and practice. The susceptible groups of COVID-19  
242 positive patients with a history of PD are elderly males with 10 years or longer duration of illness  
243 and other comorbid conditions. It is still unclear how SARS-CoV2 affects the long-term health

244 of the nervous system in PD patients. It is recommended that healthcare practitioners address  
245 diminished neurological outcomes, changes in hospital stay, and raised mortality in PD patients.

246

## 247 **7. References**

248 1. Wu, Y. C., Chen, C. S. & Chan, Y. J. The outbreak of COVID-19: An overview. *Journal*  
249 *of the Chinese Medical Association* (2020) doi:10.1097/JCMA.0000000000000270.

250 2. WHO. WHO Coronavirus Disease Dashboard. *WHO.int* (2021).

251 3. Favalli, E. G. *et al.* COVID-19 infection and rheumatoid arthritis: Faraway, so close!  
252 *Autoimmunity Reviews* (2020) doi:10.1016/j.autrev.2020.102523.

253 4. Umakanthan, S. *et al.* Origin, transmission, diagnosis and management of coronavirus  
254 disease 2019 (COVID-19). *Postgraduate Medical Journal* (2020)

255 doi:10.1136/postgradmedj-2020-138234.

256 5. Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C. & Melguizo-  
257 Rodríguez, L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.

258 *Cytokine and Growth Factor Reviews* (2020) doi:10.1016/j.cytogfr.2020.06.001.

259 6. Bhidayasiri, R., Virameteekul, S., Kim, J. M., Pal, P. K. & Chung, S. J. COVID-19: An  
260 early review of its global impact and considerations for parkinson's disease patient care.

261 *Journal of Movement Disorders* (2020) doi:10.14802/jmd.20042.

262 7. Page, M. J. *et al.* The PRISMA 2020 statement: An updated guideline for reporting  
263 systematic reviews. *The BMJ* (2021) doi:10.1136/bmj.n71.

264 8. Sarfraz, A. *et al.* Randomized controlled trials of remdesivir in hospitalized coronavirus  
265 disease 2019 patients: A meta-analysis. *Turkish J. Emerg. Med.* (2021) doi:10.4103/2452-  
266 2473.309139.

- 267 9. Cilia, R. *et al.* Effects of COVID-19 on Parkinson's Disease Clinical Features: A  
268 Community-Based Case-Control Study. *Mov. Disord.* (2020) doi:10.1002/mds.28170.
- 269 10. Del Prete, E. *et al.* Prevalence and impact of COVID-19 in Parkinson's disease: evidence  
270 from a multi-center survey in Tuscany region. *J. Neurol.* (2020) doi:10.1007/s00415-020-  
271 10002-6.
- 272 11. Zhai, H. *et al.* Characteristic of Parkinson's disease with severe COVID-19: a study of 10  
273 cases from Wuhan. *J. Neural Transm.* (2021) doi:10.1007/s00702-020-02283-y.
- 274 12. Lo Monaco, M. R., Colacicco, G., Marotta, J. & Bentivoglio, A. R. An educational case  
275 series of Parkinson's disease during the COVID-19 pandemic. *Revue Neurologique* (2021)  
276 doi:10.1016/j.neurol.2020.07.007.
- 277 13. Fasano, A. *et al.* Predictors of COVID-19 outcome in Parkinson's disease. *Park. Relat.*  
278 *Disord.* (2020) doi:10.1016/j.parkreldis.2020.08.012.
- 279 14. Filatov, A., Sharma, P., Hindi, F. & Espinosa, P. S. Neurological Complications of  
280 Coronavirus Disease (COVID-19): Encephalopathy. *Cureus* (2020)  
281 doi:10.7759/cureus.7352.
- 282 15. Brown, E. G. *et al.* The Effect of the COVID-19 Pandemic on People with Parkinson's  
283 Disease. *J. Parkinsons. Dis.* (2020) doi:10.3233/JPD-202249.
- 284 16. Kobylecki, C., Jones, T., Lim, C. K., Miller, C. & Thomson, A. M. Phenomenology and  
285 Outcomes of In-Patients With Parkinson's Disease During the Coronavirus Disease 2019  
286 Pandemic. *Movement Disorders* (2020) doi:10.1002/mds.28205.
- 287 17. Lo Monaco, M. R., Bentivoglio, A. R., Fusco, D., Calabresi, P. & Piano, C. Subacute  
288 onset dystonia in a woman affected by Parkinson's disease following SARS-COV-2  
289 infection. *Clin. Park. Relat. Disord.* (2021) doi:10.1016/j.prdoa.2020.100082.

- 290 18. Antonini, A., Leta, V., Teo, J. & Chaudhuri, K. R. Outcome of Parkinson's Disease  
291 Patients Affected by COVID-19. *Movement Disorders* (2020) doi:10.1002/mds.28104.
- 292 19. Vignatelli, L. *et al.* Risk of Hospitalization and Death for COVID-19 in People with  
293 Parkinson's Disease or Parkinsonism. *Mov. Disord.* (2021) doi:10.1002/mds.28408.
- 294 20. Artusi, C. A. *et al.* COVID-19 in Parkinson's disease: Report on prevalence and outcome.  
295 *Parkinsonism and Related Disorders* (2020) doi:10.1016/j.parkreldis.2020.09.008.
- 296 21. Santos-García, D. *et al.* Impact of Coronavirus Disease 2019 Pandemic on Parkinson's  
297 Disease: A Cross-Sectional Survey of 568 Spanish Patients. *Mov. Disord.* (2020)  
298 doi:10.1002/mds.28261.
- 299 22. Sainz-Amo, R. *et al.* COVID-19 in Parkinson's disease: what holds the key? *J. Neurol.*  
300 (2020) doi:10.1007/s00415-020-10272-0.
- 301 23. Li, J. *et al.* Management of a Parkinson's disease patient with severe COVID-19  
302 pneumonia. *Ther. Adv. Chronic Dis.* (2020) doi:10.1177/2040622320949423.
- 303 24. de Marcaida, J. A. *et al.* Clinical characteristics of coronavirus disease 2019 (COVID-19)  
304 among patients at a movement disorders center. *Geriatr.* (2020)  
305 doi:10.3390/GERIATRICS5030054.
- 306 25. Prasad, S. *et al.* Parkinson's Disease and COVID-19: Perceptions and Implications in  
307 Patients and Caregivers. *Movement Disorders* (2020) doi:10.1002/mds.28088.
- 308 26. Helmich, R. C. & Bloem, B. R. The Impact of the COVID-19 Pandemic on Parkinson's  
309 Disease: Hidden Sorrows and Emerging Opportunities. *Journal of Parkinson's Disease*  
310 (2020) doi:10.3233/JPD-202038.
- 311 27. Stoessl, A. J., Bhatia, K. P. & Merello, M. Movement Disorders in the World of COVID-  
312 19. *Movement Disorders* (2020) doi:10.1002/mds.28069.

- 313 28. Papa, S. M. *et al.* Impact of the COVID-19 Pandemic on Parkinson's Disease and  
314 Movement Disorders. *Movement Disorders Clinical Practice* (2020)  
315 doi:10.1002/mdc3.12953.
- 316 29. Mao, L. *et al.* Neurologic Manifestations of Hospitalized Patients with Coronavirus  
317 Disease 2019 in Wuhan, China. *JAMA Neurol.* (2020) doi:10.1001/jamaneurol.2020.1127.
- 318 30. Esposito, G. *et al.* Can the enteric nervous system be an alternative entrance door in  
319 SARS-CoV2 neuroinvasion? *Brain, Behavior, and Immunity* (2020)  
320 doi:10.1016/j.bbi.2020.04.060.
- 321 31. Li, Y. C., Bai, W. Z. & Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may  
322 play a role in the respiratory failure of COVID-19 patients. *Journal of Medical Virology*  
323 (2020) doi:10.1002/jmv.25728.
- 324 32. Moriguchi, T. *et al.* A first case of meningitis/encephalitis associated with SARS-  
325 Coronavirus-2. *Int. J. Infect. Dis.* (2020) doi:10.1016/j.ijid.2020.03.062.
- 326 33. Poyiadji, N. *et al.* COVID-19-associated acute hemorrhagic necrotizing encephalopathy:  
327 Imaging features. *Radiology* (2020) doi:10.1148/radiol.2020201187.
- 328 34. Beyrouti, R. *et al.* Characteristics of ischaemic stroke associated with COVID-19. *Journal*  
329 *of Neurology, Neurosurgery and Psychiatry* (2020) doi:10.1136/jnnp-2020-323586.
- 330 35. Ebrille, E. *et al.* Syncope as the presenting symptom of COVID-19 infection. *Hear. Case*  
331 *Reports* (2020) doi:10.1016/j.hrcr.2020.04.015.
- 332 36. Lechien, J. R. *et al.* Clinical and epidemiological characteristics of 1420 European patients  
333 with mild-to-moderate coronavirus disease 2019. *J. Intern. Med.* (2020)  
334 doi:10.1111/joim.13089.
- 335 37. Zanin, L. *et al.* SARS-CoV-2 can induce brain and spine demyelinating lesions. *Acta*

- 336 *Neurochir. (Wien)*. (2020) doi:10.1007/s00701-020-04374-x.
- 337 38. Rogers, J. P. *et al.* Psychiatric and neuropsychiatric presentations associated with severe  
338 coronavirus infections: a systematic review and meta-analysis with comparison to the  
339 COVID-19 pandemic. *The Lancet Psychiatry* (2020) doi:10.1016/S2215-0366(20)30203-  
340 0.
- 341 39. Toscano, G. *et al.* Guillain–Barré Syndrome Associated with SARS-CoV-2. *N. Engl. J.*  
342 *Med.* (2020) doi:10.1056/nejmc2009191.
- 343 40. Rábano-Suárez, P. *et al.* Generalized myoclonus in COVID-19. *Neurology* (2020)  
344 doi:10.1212/WNL.00000000000009829.
- 345 41. Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel  
346 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* (2020)  
347 doi:10.1001/jama.2020.1585.
- 348 42. Guo, D. *et al.* Influence of the COVID-19 Pandemic on Quality of Life of Patients with  
349 Parkinson’s Disease. *Parkinsons. Dis.* (2020) doi:10.1155/2020/1216568.
- 350 43. Lukiw, W. J., Pogue, A. & Hill, J. M. SARS-CoV-2 Infectivity and Neurological Targets  
351 in the Brain. *Cell. Mol. Neurobiol.* (2020) doi:10.1007/s10571-020-00947-7.
- 352 44. Costello, F. & Dalakas, M. C. Cranial neuropathies and COVID-19: Neurotropism and  
353 autoimmunity. *Neurology* (2020) doi:10.1212/WNL.00000000000009921.
- 354
- 355
- 356
- 357
- 358



359

360

No	Author	Study Design	Sample (N) PD	Males, %	Age, Mean	Comorbidities %	Disease duration , mean	Outcomes	PD related symptoms With COVID %
1	Cilia R et al, 2020	Case-control	12 cases 36 control	41.7 % cases 41.7% controls	65.5 years cases 66.3 years control	8.3% COPD 33.3 HTN 8.3% obesity 8.3% cardiopathy 16.7 % cancer 8.3% immuno-compromised	6.3 years cases 6.1 years control	50% affected by COVID-19 (cases group); 0% affected by COVID-19 in control group, 8.3% hospitalized	Worsening of motor symptoms
2	Del Prete, Eleonora, et al.2020	Case-control	7 cases 14 control	57.2% cases 57.2 % control	75.7 years cases versus 75 years control	Cases: 71.5% HTN 42.8% diabetes 28.5% cardiomyopathy 14.2% malignancies	9.3 years cases 8.9 years control	13 % mortality 14% case fatality	30% worsening

3	Hainque E et al, 2020	Case report	2	50 %	77.5	HTN	22y	100 %	100% worsening
4	Lo Monaco MR et al, 2020	Case series	5	66.6 %	74.2	20% Chronic Renal failure 20% Diabetes hypertension	NA	20% case fatality	60% Worsening
5	Fasano, Alfonso, et al. 2020	Case-control survey	105	52.4%	70.5	Obesity 18.1 % HTN 41.9% COPD 5.6% Diabetes 7.6% Cancer .9 %	9.9 y	17.1% hospitalized 5.7 % mortality	
6	Filatov, Asia, et al.2021	Case report	1		74	atrial fibrillation cardioembolic stroke COPD	NA	Icu hospitalization Poor prognosis	Encephalopathy
7	Brown EG, et al,	Cross sectiona	51	47 %	65	Immunocompromised 22%	0–3y 21	9.8% Hospitalized	55 % worsening

	2020	1				Heart Disease 20% HTN 25% Lung disease 14%	3–6y 12 6–9y 9 >9y 9	3.9% ICU 2% Ventilator	18 % new PD symptoms
8	Kobylecki C et al 2020	Cohort, observat ional	58	62.5 %	78.3	Diabetes 8% HTN 38%	9.5	22.4% Mortality rate	69% Delirium 54% Dementia
9	Lo Monaco MR et al, 2021	Case report	1	0%	58	NA	8 y	NA	severe spasms of arms and legs.
10	Antonini et al 2020	case series	10	60 %	78.3	Diabetes Orthostatic hypotension CHF, COPD Asthma IHD, CKD, dementia, osteoporosis	12.7 y	40% mortality rate	Worsening of mobility with fall Worsening of motor symptoms Worsening of anxiety

						anxiety disorder			
11	Vignatelli et al, 2020	cohort	696 PD  184 parkinsonism  control 8590	58.8 & PD  57.1 parkinsonism  58.2 control	75 PD 80.5 PS  Control 76.0	PD and PS 22.6 % cardiomyopathies 14.6 % Cerebrovascular disease 8.5 % Chronic pulmonary disease .3 % Liver disease 5 % Renal disease 10% DM 8.5% malignancies	NA	Hospitalization 0.6% PD 3.3% PS 0.7% control  Mortality rate 35.1% in all group	PD: 72.8% Tremor 80,4% Bradykinesia 81.6% Clinical features at onset unilateral  PS: 52.5% Tremor 89.2 % Bradykinesia 52.5% Clinical

									features at onset unilateral
12	Artusi CA,et al, 2020	multiple case reports	8	62.5%	74	HTN diabetes, depression lung neoplasm Atrial fibrillation	12.2 y	75% mortality rate	50% worsening of PD symptoms
13	Diego Santos-García et al,	cross-sectional	15	47.1%	76.3	26.7% HTN 20% DM 64.3% Dyslipidemia 13.3% Cardiomyopathy 6.7% Valvular cardiomyopathy 20% Cardiac Arrhythmia 6.7% Cardiac Insufficiency 14.3% Pulmonary	NA	33.3% Hospitalized	65.7% worsening of symptoms 47.7% bradykinesia 41.4% sleep problems 40.7% rigidity 34.5% gait disturbances 31.3%

						disease 6.7% smoking			anxiety 28.5% pain 28.3% fatigue 27.6% Depression 20.8% tremor
14	R Sainz Amo et al. 2020	Case Control	Case: 33 Control:1 72	5 59	Case:75.9 Control: 73.9	36% Dementia	Case: 8.9 Control8 .5	54% hospitalization 21% mortality rate	NA
15	Jing li et al. 2020	Case report	1	Female	85	HTN Stroke	6 y		worsening motor symptoms. Encephalopat hy
16	De Marcaida et al 2020	Retrospective	36 22 PD	64 %	74.5	HTN cardiovascular	16.2 y	67% hospitalization 36% mortality	75% Alteration

						disease renal disease, diabetes chronic lung disease immunosuppressio n			mental status  19 % worsening of their Movement abnormality  31% worsening mobility
--	--	--	--	--	--	---	--	--	---

**Table 1.** Characteristics of included studies.

361

362

363